Recent progresses in nanomedicine have provided new strategies for disease treatment, especially cancer treatment. Since FDA has approved Doxil (PEGylated liposomal doxorubicin) and Abraxane (albumin-bound paclitaxel) for clinical use and several systems are in clinical trials, various nanocarriers, e.g. liposomes, micelles, dendrimers, and polymeric nanoparticles have been designed and applied as drug nanocarriers. Owing to the small size, long systemic circulation life-time, controlled release of the payload, and targeting ability, these nanocarriers might be able to overcome the intrinsic limits of some conventional chemotherapeutic drugs (low stability, side effects, and non-specific distribution, etc.). Therefore, using nanocarriers as the drug delivery vehicles for cancer treatment is quite promising. This presentation discusses the comprehensive understandings of using nanocarriers for drug delivery in cancer treatment, as well as the obstacles and the challenges in this field.
Dr. Yike Jiang received his Ph.D. degree in Food Science from Rutgers, the State University of New Jersey in 2017, after which he joined TBSI in lab 3B as a postdoctoral fellow in 2018, supervised by Prof. Lan Ma and Prof. Ting Xu. His research interest is using nanomedicine for cancer treatment. In particular, he is working on delivery of anti-cancer drug by the targeted 3-Helix Micelle to triple-negative breast cancer cells.